MAR 10, 2015 09:00 AM PDT

Newly Updated Guidelines for the Diagnosis of Multiple Myeloma

SPONSORED BY: Binding Site, Binding Site
17 53 17045

  • Professor of Medicine & Chief of Multiple Service at Memorial Sloan-Kettering in New York City
      Dr. Landgren is Professor of Medicine and Chief Attending Physician of the Myeloma Service at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York, NY. Dr. Landgren is one of the world leaders in the field of early treatment strategies and molecular- and cell-based monitoring of minimal residual disease (MRD) detection in multiple myeloma and its precursor states. He leads a translational research program at MSKCC designed to discover new treatment paradigms integrating modern therapy and novel MRD assays. Dr. Landgren has designed and led the definitive study showing that all multiple myeloma patients are preceded by a precursor stage. As part of his ongoing research program, he is studying molecular mechanisms underlying the trajectory from precursor to full-blown multiple myeloma with the goal to develop of treatment strategies aiming to delay, prevent, and ultimately define a cure for multiple myeloma.

      Dr. Landgren has published over 250 peer-reviewed publications and he is a frequently invited speaker at national and international hematology conferences. He serves on several research committees and editorial boards for scientific journals.

    DATE: Tuesday, March 10, 2015
    TIME: 09:00 PST, 11:00 CST, 12:00 EST, 16:00 GMT

    The International Myeloma Working Group (IMWG) has issued updated criteria for the diagnosis of multiple myeloma.

    The updated criteria, published in The Lancet Oncology represent a significant change in how Multiple Myeloma is diagnosed and the stage at which patients should be treated.

    Join us on March 10th on a webinar covering these updated criteria for Myeloma and related plasma cell disorders and the importance of biomarkers in Early Stage Disease.
    Following this presentation the listener will:
    • Understand the history and traditional tools used to diagnose Myeloma
    • Gain an appreciation for the evolution of Myeloma diagnosis and biomarkers of the disease
    • Be able to understand how to apply the new diagnostic guidelines to the diagnosis and treatment of Myeloma.

    Show Resources
    Loading Comments...